Fayetteville, Arkansas, May 9, 2022: For decades, LASIK surgery has been the most prominent corrective surgery in the world. However, conditions had to be just right for patients to qualify leaving a massive gap for millions with impaired vision. Enter the EVO Visian ICL procedure.
Recently approved by the U.S. Food and Drug Administration (FDA), the FDA has granted approval of the EVO/EVO+ Visian® Implantable Collamer® Lens (“EVO”) for the correction of myopia and myopia with astigmatism. Myopia, which is also known as nearsightedness or the need for distance vision correction, is the most common vision disorder globally and its prevalence is rapidly growing.1 An estimated 100 million U.S. adults ages 21 to 45 who have myopia are potential candidates for EVO, a biocompatible implantable lens that corrects distance vision.
In layman's terms, this surgery applies to patients:
- whose eyes are ‘too bad’ for LASIK,
- who have been told there is no option for vision correction
- their only vision correction options are procedures with multiple steps or long down time
- who are candidates for LASIK but prefer an alternative reversible option
In contrast to the previously oered ICL involving multiple procedures, this new EVO lens allows patients the same convenience of LASIK: a quick procedure with a fast recovery!
While it is new to the US market, over 1,000,000 EVO ICL lenses have been implanted worldwide, with 99.4% saying they would have the procedure over again!
The first recipient in Arkansas will be a sta member at Vold Vision. Ashlie Houston is a working mom who was told no to LASIK and her only options were procedures with many appointments and a long down time. “EVO is the dream procedure I was waiting for! I’m saying goodbye to glasses and contacts and can be back on mom duty in a day!”
###
Vold Vision operates two world-class comprehensive eye care centers in Fayetteville and Bentonville Arkansas, utilizing the most advanced medical, laser, and surgical care available.
